Israel-based ophthalmic device developer EyeYon Medical has received $6.5m in funding from investors including ophthalmology product and services provider Gauss Medical, Globes reported on Tuesday.
Venture capital funds Triventures and Rimonci Capital and VC firm Pontifax joined China-headquartered Gauss in the round, which included a grant from Israel’s Office of the Chief Scientist.
EyeYon is developing ophthalmic devices to treat eye disorders. Its first product, a therapeutic contact lens to treat corneal edema, a condition where the cornea swells, has been secured regulatory approval in regions including the US and Europe.
The company is also working on another product to treat cornel edema, a silicon-film implant called EndoArt that will function as an artificial endothelial layer.
The series A funding will be used to complete a human safety and performance study for EndoArt with a view to getting regulatory approval, and to expand EyeYon’s sales and marketing.
EyeYon had previously raised $4.3m in funding, $3.6m of which came in an April 2015 round featuring TriVentures, Pontifax, an unnamed India-based medical distributor, the Israeli Office of the Chief Scientist and Docor International, part of charitable foundation Van Leer Group Foundation.
– Image courtesy of EyeYon Medical